Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341508 · ClinicalTrials.gov registry record · Phase 1
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
A Phase 1 study, sponsored by Lpath.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02341508 is a Phase 1 study that has completed, run by Lpath. The registered enrollment target is 36 participants.
The verdict
NCT02341508, a Phase 1 study, has completed, sponsored by Lpath.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of Lpathomab in healthy volunteers. Additional endpoints include characterization of the pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity profiles of a single IV dose of Lpathomab in healthy volunteers.
Interventions
- BIOLOGICAL 0.5 mg/kg Lpathomab
- BIOLOGICAL 1.0 mg/kg Lpathomab
- BIOLOGICAL 3.0 mg/kg Lpathomab
- BIOLOGICAL 10 mg/kg Lpathomab
- BIOLOGICAL 20 mg/kg Lpathomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341508
The ClinicalTrials.gov registry entry for NCT02341508 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lpath, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 0.5 mg/kg Lpathomab is the first listed.
NCT02341508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341508 about?
NCT02341508 is a clinical study titled "A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers". The primary purpose of this study is to evaluate the safety and tolerability of Lpathomab in healthy volunteers. Additional endpoints include characterization of the pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity profiles of a single IV dose of Lpathomab in healthy volunteers.
What is the current status of trial NCT02341508?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02341508?
The interventions under investigation include: 0.5 mg/kg Lpathomab (BIOLOGICAL), 1.0 mg/kg Lpathomab (BIOLOGICAL), 3.0 mg/kg Lpathomab (BIOLOGICAL), 10 mg/kg Lpathomab (BIOLOGICAL), 20 mg/kg Lpathomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02341508?
This trial is sponsored by Lpath, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.